NDAORALTABLET
Approved
Aug 2017
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NIKITA (pitavastatin sodium) by Lupin Ltd. is 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase, the enzyme that catalyzes the conversion of hmg-coa to mevalonate, a rate-limiting step in the biosynthetic pathway for cholesterol. First approved in 2017.
Drug data last refreshed 4h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NIKITA is a pitavastatin sodium tablet, an oral statin that inhibits HMG-CoA reductase to reduce cholesterol synthesis in the liver. It lowers plasma total cholesterol and VLDL by accelerating LDL-receptor expression and hepatic uptake of LDL from the bloodstream. NIKITA is indicated for patients requiring lipid management to reduce cardiovascular risk.
Peak
At peak lifecycle stage with moderate competitive pressure (30%), the brand team is likely maintaining market position rather than driving rapid growth.
Mechanism of Action
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, a rate-limiting step in the biosynthetic pathway for cholesterol. As a result, the expression of LDL-receptors followed by the uptake of LDL from blood to liver is…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NIKITA offers exposure to a mature, established therapeutic category with proven commercial infrastructure and established healthcare relationships. Career growth is likely incremental rather than transformational, with emphasis on market defense and operational excellence rather than innovation.
Brand Manager
Worked on NIKITA at Lupin Ltd.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.